Measurement of Microvessel Density Using CD105 (Endoglin) as a Marker in Prostatic Adenocarcinoma

Abstract

Introduction Angiogenesis has been proposed as a promising prognostic marker in a variety of tumours. Microvessel density (MVD) measurement is the most reliable method for the semiquantitative evaluation of angiogenesis. Endoglin (CD105) is a recognised marker of proliferating endothelium and is expressed in intra-tumoral as well as peri-tumoral vessels. It is upregulated in various cancers including prostate cancer, therefore, it is an upcoming prime marker for prognosis, tumour imaging and antiangiogenesis therapy. Aim The study was done to evaluate microvessel density (MVD) by using CD105 (endoglin) as an IHC marker in prostatic adenocarcinoma and to find its relationship with Gleason score and grade groups. Materials and methods This was an observational cross-sectional study under which a total of 31 histopathologically diagnosed cases of prostatic adenocarcinoma on TURP chips were included and were graded according to Gleason score and grades.IHC using endoglin (CD105) was done to detect the highest-density areas of stained vessels (hot spots). The highest value obtained in three hot spot fields was reported as microvessel density (MVD) and its relationship with Gleason score and grade groups was analysed. Results Most common age group was 71-80 years (48.39% cases). Maximum cases (45.16%) had a Gleason score of 9. The maximum mean MVD CD105 score was found in the Gleason grade group 5 (45.32%) while the minimum was in grade group 1 (24%). Comparison of mean MVD CD105 scores in different Gleason grade groups revealed a significant association of MVD CD105 with Gleason grade groups. Conclusion Endoglin measures microvessel density and its expression correlated with Gleason score and grade group. Hence it can be used as a potential prognostic marker in adenocarcinoma prostate.